AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19435954
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy using a closed-loop system (AP group)
Trial: 19435954
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy using the sliding-scale method (SS group)
Trial: 17302746
Drug: 1% luliconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% luliconazole cream
Trial: 17302746
Drug: 0.5% luliconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% luliconazole cream
Trial: 17302746
Drug: 0.1% luliconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% luliconazole cream
Trial: 15366590
Drug: Shuizhitong capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuizhitong capsule (SZT)
Trial: 1827011
Drug: Isradipine MR
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine MR 5 mg once daily
Trial: 1827011
Drug: Isradipine MR
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine MR 10 mg once daily
Trial: 1827011
Drug: Isradipine given
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine given twice daily (13 +/- 2 mg total daily dose)
Trial: 1827011
Drug: Modified-release isradipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release isradipine (isradipine MR) once daily
Trial: 766142
Drug: Prednisolone 3
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 3 mg
Trial: 30608465
Drug: EHR-generated medication
RxNorm normalized name: Ehrlichia canis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHR-generated medication lists in admission packets
Trial: 21330250
Drug: Cobalt-chromium drug-eluting
RxNorm normalized name: Cobalt
DrugBank: Cobalt (DB14574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt-chromium drug-eluting stents
Trial: 21330250
Drug: Stainless steel
RxNorm normalized name: stainless steel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stainless steel drug-eluting stents
Trial: 19183164
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a quantified peach extract for Pru p 3, duration: 6 months
Trial: 19183164
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with a quantified peach extract for Pru p 3
Trial: 15277165
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g/d)
Trial: 11808847
Drug: Oxytocin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (16 IU) administered intranasally to 49 subjects
Trial: 11808847
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group of 54 subjects with no prior oxytocin treatment
Trial: 9735932
Drug: Microencapsulated lambdacyhalothrin
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microencapsulated lambdacyhalothrin for bednet treatment
Trial: 2902642
Drug: Zuclopenthixol decanoate
RxNorm normalized name: zuclopenthixol decanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zuclopenthixol decanoate injection (mean dosage 123 mg/week)
Trial: 30427829
Drug: rcAd26.MOS1.HIV‐Env vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rcAd26.MOS1.HIV‐Env vaccine (10^8 to 10^11 rcAd26 VP)
Trial: 25374187
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (4,500 cGy of radiation at 180 cGy per day plus chemotherapy with cisplatin and 5‐fluorouracil, in the first and the end four days of radiotherapy)
Trial: 17981439
Drug: Flaxseed (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (40 g daily for 12 months)
Trial: 15514916
Drug: Corticosteroids as
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids as part of antileukemic therapy
Trial: 12351462
Drug: Repaglinide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (4 mg t.i.d.)
Trial: 12351462
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 or 1,000 mg t.i.d., dose unchanged)
Trial: 30126325
Drug: Lidocaine/Phenylephrine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/Phenylephrine administered with a nasal nebulizer
Trial: 30126325
Drug: Lidocaine/Phenylephrine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/Phenylephrine administered with a nasal spray
Trial: 24533048
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) 80 ppm
Trial: 23059166
Drug: Quetiapine XR
RxNorm normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine XR (extended-release)
Trial: 23059166
Drug: Quetiapine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine IR (immediate-release)
Trial: 16792320
Drug: Aprotinin in
RxNorm normalized name: aprotinin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin in the dose of 3 ppm KIU
Trial: 8533869
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (NP) infusion for 60 min, decreasing mean arterial blood pressure to 50 mm Hg.
Trial: 8533869
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no NP infusion).
Trial: 8533869
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (NP) infusion for 60 min.
Trial: 31599043
Drug: 25.2 g
RxNorm normalized name: Veltassa 25.2 GM Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25.2 g oral patiromer plus standard of care (SOC)
Trial: 28188124
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioral therapy for insomnia (CCBT‐I) as an adjunctive treatment
Trial: 17577465
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg BID
Trial: 17577465
Drug: Dipyrone 1000
RxNorm normalized name: dipyrone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 1000 mg QID
Trial: 7036196
Drug: Isocarboxazid (Marplan)
RxNorm normalized name: isocarboxazid Oral Tablet [Marplan]
DrugBank: Isocarboxazid (DB01247)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isocarboxazid (Marplan) 20 mg daily, increased to achieve 90% platelet MAO inhibition
Trial: 30928020
Drug: Platelet treatment
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet treatment
Trial: 30928020
Drug: TGF-β type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-β type I receptor (TβR I) inhibitor A83-01
Trial: 25378647
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl (low dose, 1/50th of rescue morphine dose)
Trial: 25378647
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl (high dose, 1/25th of rescue morphine dose)
Trial: 25378647
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (active control)
Trial: 15203809
Drug: Small lapses
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small lapses during treatment
Trial: 15203809
Drug: Interaction between
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interaction between drug treatment and lapse history
Trial: 11943448
Drug: Subcutaneous interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous interleukin-2 (IL-2) plus antiretroviral therapy
Trial: 8464953
Drug: 60 lux
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 lux light therapy
Trial: 8464953
Drug: 600 lux
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 lux light therapy
Trial: 8464953
Drug: 3500 lux
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3500 lux light therapy
Trial: 8464953
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three intensities of light therapy
Trial: 3515509
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts (ORS) from effervescent tablets containing citrate
Trial: 27654733
Drug: Topical dexamethasone
RxNorm normalized name: dexamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dexamethasone (0.1% eye drops)
Trial: 27654733
Drug: Sub-tenon triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sub-tenon triamcinolone injection (40mg/1ml)
Trial: 10606453
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation (seven treatment sessions)
Trial: 10606453
Drug: Sham radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham radiation (one sham treatment session)
Trial: 31477558
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily for 8 weeks (run-in phase)
Trial: 31477558
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg or 300 mg or matched placebo (double-blind randomisation)
Trial: 25172777
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg
Trial: 17692271
Drug: Valacyclovir (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (500 mg tablet daily)
Trial: 17692271
Drug: Acyclovir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (400 mg tablet twice daily)
Trial: 11953546
Drug: Functional Electric
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electric Stimulation (FES) therapy for short-duration hemiplegia, 6 hours a day for 6 weeks.
Trial: 11953546
Drug: Functional Electric
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional Electric Stimulation (FES) therapy for long-duration hemiplegia, 6 hours a day for 6 weeks.
Trial: 11953546
Drug: Second 6-week
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Second 6-week FES therapy after the first 6-week therapy for both short and long-duration groups.
Trial: 9525433
Drug: Nonoxynol-9 (N-9)
RxNorm normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol-9 (N-9) 100 mg daily for 1 week
Trial: 2676652
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg fenticonazole (single administration)
Trial: 2676652
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg clotrimazole (single administration)
Trial: 30584131
Drug: L-Arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Arginine supplementation
Trial: 29081128
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy and high pressure oxygen (Control)
Trial: 25935844
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant spray (control)
Trial: 25935844
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant spray and pop of an empty J‐Tip (sham)
Trial: 19079970
Drug: Conventional assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional assisted reproduction treatment (Control)
Trial: 15823628
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with diet, anti-hypertensive or antidiabetic drugs
Trial: 8746880
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg estriol vaginal suppositories
Trial: 8746880
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg estriol vaginal suppositories
Trial: 28779007
Drug: Dexamethasone implants
RxNorm normalized name: dexamethasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone implants
Trial: 22648841
Drug: HIIC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIC + Parenteral Nutrition (HIIC+PN)
Trial: 20931801
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive drospirenone/ethinyl E2 (group 1)
Trial: 20931801
Drug: Norelgestromin/ethinyl E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norelgestromin/ethinyl E2 transdermal patch (group 2)
Trial: 2020272
Drug: Naloxone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (20 mg)
Trial: 28062296
Drug: Atorvastatin after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin after 8 weeks
Trial: 25091668
Drug: Withholding breastfeeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withholding breastfeeding during the 30 min prior to and after each vaccine dose
Trial: 25091668
Drug: Breastfeeding during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breastfeeding during the 30 min prior to and after each vaccine dose
Trial: 22815003
Drug: Esmolol drip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol drip (0.2‐0.5 mg/kg bolus followed by continuous infusion of 212.5 ± 63.5 mg/h to 272.5 ± 89.5 mg/h over 24 hours)
Trial: 17156345
Drug: Combined topical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined topical steroid (extra-fine inhaled beclomethasone 400 mcg/day and intranasal beclomethasone 200 mcg/day)
Trial: 17156345
Drug: Combined mediator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined mediator antagonism (montelukast 10 mg and cetirizine 10 mg)
Trial: 10612317
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (120 mg/d)
Trial: 7675241
Drug: 0.5 mg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/hr levodopa infusion
Trial: 7675241
Drug: 1.0 mg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg/hr levodopa infusion
Trial: 7675241
Drug: 0.0 mg/kg/hr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0 mg/kg/hr levodopa infusion (placebo)
Trial: 7002059
Drug: Intrathecal antitetanus
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal antitetanus serum with steroid
Trial: 24565542
Drug: Combination budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination budesonide/formoterol as maintenance and reliever therapy
Trial: 24565542
Drug: Combination budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination budesonide/formoterol as maintenance treatment with albuterol as reliever
Trial: 10396923
Drug: Regular outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular outpatient treatment (3 months)
Trial: 10396923
Drug: Extended outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended outpatient treatment (6 months)
Trial: 7993599
Drug: Sealants applied
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants applied with a drying agent
Trial: 7993599
Drug: Sealants applied
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants applied without a drying agent
Trial: 4881341
Drug: Aqueous vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aqueous vasopressin injection (Pitressin)
Trial: 29637896
Drug: Mg lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg lactate (MgLact2) supplementation
Trial: 22134732
Drug: Antiresorptive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive agents combined with repeated PVPs
Trial: 19920001
Drug: Revascularization plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revascularization plus intensive medical therapy
Trial: 19920001
Drug: Insulin provision
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin provision therapy
Trial: 9868028
Drug: Musical relaxation
RxNorm normalized name: Relax-DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Musical relaxation therapy
Trial: 3646613
Drug: Self-administered pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered pain medication
Trial: 3646613
Drug: Nurse-administered pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered pain medication
Trial: 29940151
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment arm (blood pressure target <= 120 mmHg)
Trial: 29940151
Drug: Combined effect
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined effect of pulse pressure and treatment intensity
Trial: 25137430
Drug: Dexmedetomidine continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine continuous infusion at a rate of 0.4 μg kg(‐1) hour(‐1)
Trial: 16796717
Drug: Pulse corticosteroid
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse corticosteroid therapy
Trial: 16796717
Drug: Randomized clinical
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized clinical trial of biopsy and corticosteroid therapy
Trial: 9020413
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate 10 mg plus terbutaline 0.5 mg (group A)
Trial: 9020413
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus terbutaline 0.5 mg (group B)
Trial: 1413302
Drug: Gentamicin sulfate,
RxNorm normalized name: Gentamicin Sulfate, Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin sulfate, 80 mg, administered 8-hourly for a total of three doses, starting just prior to the operation
Trial: 4042543
Drug: Alcohol (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.9 g/kg)
Trial: 4042543
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 ml of orange juice)
Trial: 31206016
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg) for 24 weeks
Trial: 31206016
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 mg) for 24 weeks
Trial: 26871968
Drug: Bismuth potassium
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days with left lateral horizontal position for 30 min after dosing (GS group 1)
Trial: 26871968
Drug: Bismuth potassium
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days (GS group 2)
Trial: 25521726
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg/day
Trial: 20849620
Drug: 8 or
RxNorm normalized name: K-8 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 or 16 fluid ounces of vegetable juice daily
Trial: 20849620
Drug: 0 fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 fluid ounces of vegetable juice daily (Control)
Trial: 17761704
Drug: Dose intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose intensified E (epirubicin) followed by taxane